Psoriasis Clinical Trial

A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam

Summary

The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.

View Full Description

Full Description

Same as above.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects must have a clinical diagnosis of moderate to severe plaque psoriasis, defined as 3%-20% of the body surface area involved

Exclusion Criteria:

Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® spray or more than 50 grams per week of Olux® foam
Subjects whose psoriasis involves the scalp, face or groin
Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

78

Study ID:

NCT00436540

Recruitment Status:

Completed

Sponsor:

Galderma R&D

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Solano Clinical Research
Vallejo California, 94589, United States
Central Dermatology, PC
Saint Louis Missouri, 63117, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

78

Study ID:

NCT00436540

Recruitment Status:

Completed

Sponsor:


Galderma R&D

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider